KOICHI TAKAHASHI

TitleAssistant Professor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763. PMID: 35512188.
      Citations:    Fields:    
    2. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393. PMID: 35533245.
      Citations:    Fields:    
    3. Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014. PMID: 35533262.
      Citations:    Fields:    Translation:Humans
    4. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 Jun 15; JCO2102823. PMID: 35704787.
      Citations:    Fields:    
    5. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043. PMID: 35583199.
      Citations: 1     Fields:    Translation:Humans
    6. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022 05 19; 13(1):2801. PMID: 35589701.
      Citations:    Fields:    Translation:AnimalsCells
    7. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77. PMID: 35501304.
      Citations:    Fields:    Translation:Humans
    8. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448. PMID: 35411096.
      Citations:    Fields:    
    9. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360. PMID: 35483396.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    10. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 May; 28(5):1097. PMID: 35484266.
      Citations:    Fields:    
    11. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 Sep; 63(9):2161-2170. PMID: 35442137.
      Citations:    Fields:    
    12. Takahashi K. Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies. J Natl Cancer Inst. 2022 04 11; 114(4):487-488. PMID: 34963009.
      Citations:    Fields:    Translation:Humans
    13. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204. PMID: 35266566.
      Citations:    Fields:    Translation:HumansCells
    14. Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, Bah I, Wang W, Konoplev S, Medeiros LJ, Pemmaraju N, Khoury JD, Wang SA. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022 05; 36(5):1343-1350. PMID: 35279700.
      Citations: 1     Fields:    Translation:HumansCells
    15. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 03; 28(3):557-567. PMID: 35241842.
      Citations:    Fields:    Translation:HumansCells
    16. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921. PMID: 34601571.
      Citations: 1     Fields:    Translation:HumansCells
    17. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260. PMID: 35132195.
      Citations:    Fields:    Translation:HumansCells
    18. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10. PMID: 35078972.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    19. Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5. PMID: 35017466.
      Citations: 1     Fields:    Translation:HumansCells
    20. El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 03; 57(3):370-376. PMID: 34992253.
      Citations:    Fields:    Translation:Humans
    21. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298. PMID: 34876697.
      Citations:    Fields:    
    22. Kuipers J, Moore AL, Jahn K, Schraml P, Wang F, Morita K, Futreal PA, Takahashi K, Beisel C, Moch H, Beerenwinkel N. Statistical tests for intra-tumour clonal co-occurrence and exclusivity. PLoS Comput Biol. 2021 12; 17(12):e1009036. PMID: 34910733.
      Citations:    Fields:    Translation:HumansCells
    23. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad F, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia T, Garcia-Manero G, Garris R, O'Brien S, Jabbour E. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419. PMID: 34525185.
      Citations:    Fields:    Translation:Humans
    24. Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739. PMID: 34115096.
      Citations: 1     Fields:    Translation:Humans
    25. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071. PMID: 34663807.
      Citations: 3     Fields:    Translation:HumansCells
    26. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma. 2021 12; 62(14):3501-3505. PMID: 34474640.
      Citations:    Fields:    Translation:Humans
    27. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, Dinardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428. PMID: 34351647.
      Citations: 2     Fields:    Translation:Humans
    28. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    29. Shi X, Jiang Y, Kitano A, Hu T, Murdaugh RL, Li Y, Hoegenauer KA, Chen R, Takahashi K, Nakada D. Nuclear NAD+ homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv. 2021 07; 7(30). PMID: 34290089.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    30. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021 10 15; 127(20):3772-3781. PMID: 34255353.
      Citations: 12     Fields:    Translation:Humans
    31. Rivera D, Takahashi K, Durand JB, Ferrajoli A. Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder. Mediterr J Hematol Infect Dis. 2021; 13(1):e2021044. PMID: 34276913.
      Citations:    
    32. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389. PMID: 34138471.
      Citations: 1     Fields:    Translation:HumansCells
    33. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262. PMID: 34135465.
      Citations: 3     Fields:    Translation:Humans
    34. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778. PMID: 34043428.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    35. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98. PMID: 34016956.
      Citations: 5     Fields:    Translation:HumansCells
    36. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    37. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763. PMID: 32236406.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    38. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607. PMID: 33972549.
      Citations: 12     Fields:    Translation:HumansCells
    39. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823. PMID: 33972555.
      Citations: 1     Fields:    
    40. Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, Castelli FA, Gales L, Turtoi E, Montersino C, Farge T, Boet E, Broin N, Larrue C, Baran N, Cissé MY, Conti M, Loric S, Kaoma T, Hucteau A, Zavoriti A, Sahal A, Mouchel PL, Gotanègre M, Cassan C, Fernando L, Wang F, Hosseini M, Chu-Van E, Le Cam L, Carroll M, Selak MA, Vey N, Castellano R, Fenaille F, Turtoi A, Cazals G, Bories P, Gibon Y, Nicolay B, Ronseaux S, Marszalek JR, Takahashi K, DiNardo CD, Konopleva M, Pancaldi V, Collette Y, Bellvert F, Jourdan F, Linares LK, Récher C, Portais JC, Sarry JE. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 05 03; 218(5). PMID: 33760042.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    41. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124. PMID: 33914911.
      Citations:    Fields:    Translation:Humans
    42. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183. PMID: 33885753.
      Citations: 4     Fields:    Translation:Humans
    43. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    44. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647. PMID: 33823073.
      Citations: 4     Fields:    Translation:HumansCells
    45. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499. PMID: 33793970.
      Citations: 4     Fields:    Translation:Humans
    46. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598. PMID: 33639000.
      Citations: 7     Fields:    Translation:Humans
    47. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898. PMID: 32499238.
      Citations: 13     Fields:    Translation:Humans
    48. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34. PMID: 33618754.
      Citations:    Fields:    
    49. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063. PMID: 33618432.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    50. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E154-E157. PMID: 33580980.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25. PMID: 33563904.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    52. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213. PMID: 33585199.
      Citations: 5     
    53. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291. PMID: 33264443.
      Citations: 15     Fields:    Translation:Humans
    54. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. PMID: 33681815.
      Citations: 9     Fields:    Translation:Humans
    55. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250. PMID: 33180322.
      Citations: 4     Fields:    Translation:Humans
    56. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 11 24; 4(22):5681-5689. PMID: 33211826.
      Citations: 11     Fields:    Translation:Humans
    57. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53. PMID: 33156969.
      Citations: 3     Fields:    Translation:Humans
    58. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996. PMID: 33214561.
      Citations: 3     Fields:    
    59. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390. PMID: 33119202.
      Citations: 1     Fields:    Translation:HumansCells
    60. Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020 11; 52(11):1219-1226. PMID: 33106634.
      Citations: 80     Fields:    Translation:Humans
    61. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327. PMID: 33087716.
      Citations: 66     Fields:    Translation:HumansAnimals
    62. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132. PMID: 33032648.
      Citations: 7     Fields:    Translation:Humans
    63. Lee SE, Wang F, Trujillo-Ocampo A, Ruiz-Vasquez W, Cho HW, Takahashi K, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. EJHaem. 2020 Nov; 1(2):552-557. PMID: 35844984.
      Citations:    
    64. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329. PMID: 32886803.
      Citations:    Fields:    Translation:HumansCells
    65. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    66. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315. PMID: 32804409.
      Citations:    Fields:    Translation:Humans
    67. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576. PMID: 32856987.
      Citations: 3     Fields:    Translation:HumansCells
    68. Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol. 2020; 10:1538. PMID: 32984009.
      Citations: 1     
    69. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533. PMID: 32589978.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    70. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924. PMID: 32546726.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    71. Aitken MJL, Benton CB, Wang F, Zhang J, Herbrich SM, Takahashi K, Bueso-Ramos CE, Short NJ. Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patient. Am J Hematol. 2020 09; 95(9):1117-1120. PMID: 32356323.
      Citations:    Fields:    Translation:Humans
    72. Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677. PMID: 32324887.
      Citations: 9     Fields:    Translation:Humans
    73. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320. PMID: 32251497.
      Citations: 38     Fields:    Translation:Humans
    74. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the ß-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269. PMID: 32068780.
      Citations: 9     Fields:    Translation:HumansCells
    75. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622. PMID: 32112433.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    76. Wang W, Beird H, Kroll CJ, Hu S, Bueso-Ramos CE, Fang H, Tang G, Tang Z, Wang F, Takahashi K, You MJ, Khoury JD, Medeiros LJ, Futreal PA. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia. 2020 09; 34(9):2509-2512. PMID: 32099038.
      Citations: 5     Fields:    Translation:HumansCells
    77. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495. PMID: 32027746.
      Citations: 20     Fields:    Translation:Humans
    78. Tanaka H, Atagi K, Tatsumichi T, Yamaguchi K, Takahashi K, Kaji M, Kosaka S, Houchi H. Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients. J Chemother. 2020 Apr; 32(2):83-87. PMID: 31957595.
      Citations:    Fields:    Translation:Humans
    79. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150. PMID: 31682008.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    80. Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774. PMID: 31742675.
      Citations: 16     Fields:    Translation:Humans
    81. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    82. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488. PMID: 31400961.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    83. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4. PMID: 31344256.
      Citations: 2     Fields:    Translation:Humans
    84. Hu T, Morita K, Hill MC, Jiang Y, Kitano A, Saito Y, Wang F, Mao X, Hoegenauer KA, Morishita K, Martin JF, Futreal PA, Takahashi K, Nakada D. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells. Blood. 2019 08 15; 134(7):614-625. PMID: 31270104.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    85. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    86. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    87. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73. PMID: 31023702.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    88. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933. PMID: 30902805.
      Citations: 21     Fields:    Translation:Humans
    89. Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 06; 94(6):E158-E160. PMID: 30838674.
      Citations: 6     Fields:    Translation:Humans
    90. Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241. PMID: 30861111.
      Citations: 5     Fields:    Translation:Humans
    91. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552. PMID: 30830579.
      Citations: 13     Fields:    Translation:Humans
    92. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518. PMID: 30760466.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    93. Takahashi K. Germline polymorphisms and the risk of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2019 03; 32(1):24-30. PMID: 30927971.
      Citations: 1     Fields:    Translation:HumansCells
    94. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1). PMID: 30709875.
      Citations: 11     Fields:    Translation:Humans
    95. Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7. PMID: 30651532.
      Citations: 25     Fields:    Translation:Humans
    96. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1. PMID: 30635233.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    97. Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist. 2019 06; 24(6):772-782. PMID: 30446581.
      Citations: 12     Fields:    Translation:Humans
    98. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    99. Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 01 01; 37(1):7-11. PMID: 30403571.
      Citations: 14     Fields:    Translation:Humans
    100. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, Marszalek JR, Bristow C, Yan Y, Garcia-Manero G, Kantarjian H, Vassiliou G, Futreal PA, Donehower LA, Takahashi K, Goodell MA. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6. PMID: 30388424.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    101. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    102. Pellegrino M, Sciambi A, Treusch S, Durruthy-Durruthy R, Gokhale K, Jacob J, Chen TX, Geis JA, Oldham W, Matthews J, Kantarjian H, Futreal PA, Patel K, Jones KW, Takahashi K, Eastburn DJ. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. Genome Res. 2018 09; 28(9):1345-1352. PMID: 30087104.
      Citations: 58     Fields:    Translation:HumansCells
    103. Takahashi K. AML: Predicting the Unpredictable. Cell Stem Cell. 2018 08 02; 23(2):162-163. PMID: 30075128.
      Citations:    Fields:    Translation:HumansCells
    104. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670. PMID: 29991687.
      Citations: 26     Fields:    Translation:HumansCells
    105. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984.
      Citations: 27     Fields:    Translation:Humans
    106. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    107. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797. PMID: 29702001.
      Citations: 66     Fields:    Translation:Humans
    108. Takahashi K. Ups and downs of CHIP. Blood. 2018 04 19; 131(16):1773-1774. PMID: 29674353.
      Citations:    Fields:    Translation:HumansCells
    109. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018 07 01; 124(13):2704-2713. PMID: 29682723.
      Citations: 11     Fields:    Translation:Humans
    110. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    111. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    112. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241. PMID: 29338567.
      Citations: 5     Fields:    Translation:Humans
    113. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727. PMID: 29515765.
      Citations: 23     Fields:    
    114. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168. PMID: 29266206.
      Citations: 11     Fields:    Translation:Humans
    115. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      Citations: 45     Fields:    Translation:Humans
    116. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774.
      Citations: 26     Fields:    
    117. Takahashi K, Wang F, Kantarjian H, Song X, Patel K, Neelapu S, Gumbs C, Little L, Tippen S, Thornton R, DiNardo CD, Ravandi F, Bueso-Ramos C, Zhang J, Wu X, Garcia-Manero G, Futreal PA. Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv. 2017 Jun 27; 1(15):1031-1036. PMID: 29296745.
      Citations: 15     Fields:    
    118. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724. PMID: 28608976.
      Citations: 7     Fields:    Translation:Humans
    119. Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606. PMID: 28370097.
      Citations: 17     Fields:    Translation:HumansCells
    120. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922.
      Citations: 15     Fields:    Translation:Humans
    121. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587. PMID: 28246192.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    122. Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. N Engl J Med. 2017 02 23; 376(8):796-7. PMID: 28229579.
      Citations: 12     Fields:    
    123. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366. PMID: 28178232.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    124. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111. PMID: 27923552.
      Citations: 100     Fields:    Translation:HumansCells
    125. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624. PMID: 27601000.
      Citations: 5     Fields:    Translation:Humans
    126. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343. PMID: 27509035.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    127. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73. PMID: 27521329.
      Citations: 3     Fields:    Translation:Humans
    128. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491. PMID: 27463065.
      Citations: 71     Fields:    
    129. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep. 2016 Aug; 4(8):765-7. PMID: 27525080.
      Citations: 1     
    130. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7. PMID: 27175025.
      Citations: 2     Fields:    Translation:Humans
    131. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2. PMID: 27210295.
      Citations: 31     Fields:    Translation:Humans
    132. Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016 Mar 22; 7(12):14251-8. PMID: 26883102.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    133. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87. PMID: 26871476.
      Citations: 35     Fields:    Translation:HumansCells
    134. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol. 2016 Jun; 91(4):E274-6. PMID: 26798971.
      Citations: 1     Fields:    Translation:Humans
    135. Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016 May; 44:1-7. PMID: 26970171.
      Citations: 9     Fields:    Translation:HumansCells
    136. Shindo Y, Iwamoto K, Mouri K, Hibino K, Tomita M, Kosako H, Sako Y, Takahashi K. Conversion of graded phosphorylation into switch-like nuclear translocation via autoregulatory mechanisms in ERK signalling. Nat Commun. 2016 Jan 20; 7:10485. PMID: 26786866.
      Citations: 25     Fields:    Translation:AnimalsCells
    137. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2. PMID: 26752456.
      Citations: 8     Fields:    Translation:Humans
    138. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48. PMID: 26479889.
      Citations: 16     Fields:    Translation:Humans
    139. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74. PMID: 26547258.
      Citations: 20     Fields:    Translation:HumansCells
    140. Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol. 2015 Nov; 90(11):E211-2. PMID: 26257212.
      Citations: 2     Fields:    Translation:HumansCells
    141. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140.
      Citations: 28     Fields:    Translation:HumansCells
    142. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol. 2015 Aug; 90(8):752-3. PMID: 25850565.
      Citations: 3     Fields:    Translation:Humans
    143. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6. PMID: 26016821.
      Citations: 102     Fields:    Translation:Humans
    144. Takahashi K, Roh W, Zhang J, Propotopov A, Patel K, Strickland S, Kim A, Vnencak-Jones C, Pelletier S, Parmar S, Garcia-Manero G, Kornblau S, Chin L, Kantarjian H, Futreal PA, Ravandi F. Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5. PMID: 25801490.
      Citations: 1     Fields:    Translation:HumansCells
    145. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5. PMID: 26105212.
      Citations: 2     Fields:    Translation:HumansCells
    146. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4. PMID: 25107338.
      Citations: 15     Fields:    Translation:Humans
    147. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6. PMID: 24068492.
      Citations: 8     Fields:    Translation:Humans
    148. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013 Oct; 14(10):703-18. PMID: 24022702.
      Citations: 243     Fields:    Translation:Humans
    149. Nozaki T, Kaizu K, Pack CG, Tamura S, Tani T, Hihara S, Nagai T, Takahashi K, Maeshima K. Flexible and dynamic nucleosome fiber in living mammalian cells. Nucleus. 2013 Sep-Oct; 4(5):349-56. PMID: 23945462.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    150. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920. PMID: 23896412.
      Citations: 17     Fields:    Translation:Humans
    151. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    152. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      Citations: 25     Fields:    Translation:Humans
    153. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-66. PMID: 23530930.
      Citations: 11     Fields:    Translation:HumansCells
    154. Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol. 2013 Mar; 15(3):309-16. PMID: 23434824.
      Citations: 102     Fields:    Translation:AnimalsCells
    155. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5. PMID: 23391517.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    156. Takahashi K, Muratani T, Akasaka S, Yamada Y, Matsumoto T. The efficacy of sequential therapy using pazufloxacin followed by oral fluoroquinolones for treatment of pyelonephritis. J Infect Chemother. 2013 Jun; 19(3):456-64. PMID: 23188166.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    157. Takahashi K, Yabe M, Shapira I, Pierce S, Garcia-Manero G, Varma M. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leuk Res. 2012 Nov; 36(11):1376-9. PMID: 22917767.
      Citations: 4     Fields:    Translation:Humans
    158. Kato S, Takahashi K, Ayabe K, Samad R, Fukaya E, Friedmann P, Varma M, Bergmann SR. Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. Br J Haematol. 2011 Aug; 154(3):373-7. PMID: 21615718.
      Citations: 9     Fields:    Translation:Humans
    159. Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M, Yamamoto H, Asano-Mori Y, Matsuno N, Masuoka K, Wake A, Miyakoshi S, Ohashi K, Taniguchi S. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010 Jul 29; 116(4):649-52. PMID: 20439618.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    160. Kumamoto Y, Tsukamoto T, Matsukawa M, Kunishima Y, Yamaguti O, Ishibashi K, Hirose T, Suzutani T, Shigeta S, Yoshida H, Imafuku Y, Murai M, Oka T, Kitamura M, Watanabe K, Kobayashi Y, Uchida H, Fukuhara Y, Matsuda S, Kamidono S, Sato S, Arakawa S, Fujime M, Fujita K, Kumon H, Monden K, Igari J, Matsumoto T, Takahashi K, Oguri T, Naito S, Egashira T, Konishi T, Yamaguchi K, Furuya N, Kohno S, Deguchi T, Ishihara S, Hirakata Y, Kondo A, Matsuda J, Nakano M, Ooe H, Suzuki Y, Nishikawa M. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). II. Background of patients]. Jpn J Antibiot. 2005 Dec; 58(6):544-56. PMID: 16521345.
      Citations:    Fields:    Translation:HumansCells
    161. Takahashi T, Murata T, Omori M, Kosaka H, Takahashi K, Yonekura Y, Wada Y. Quantitative evaluation of age-related white matter microstructural changes on MRI by multifractal analysis. J Neurol Sci. 2004 Oct 15; 225(1-2):33-7. PMID: 15465083.
      Citations: 11     Fields:    Translation:Humans
    162. Muratani T, Iihara K, Nishimura T, Inatomi H, Fujimoto N, Kobayashi T, Yamada Y, Takahashi K, Matsumoto T. [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. Kansenshogaku Zasshi. 2002 Nov; 76(11):928-38. PMID: 12508476.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    163. Miyata M, Takano H, Takahashi K, Sasaki YF, Yamazoe Y. Suppression of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced DNA damage in rat colon after grapefruit juice intake. Cancer Lett. 2002 Sep 08; 183(1):17-22. PMID: 12049810.
      Citations: 6     Fields:    Translation:Animals
    164. Okada Y, Okada N, Nakagawa S, Mizuguchi H, Kanehira M, Nishino N, Takahashi K, Mizuno N, Hayakawa T, Mayumi T. Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Lett. 2002 Mar 08; 177(1):57-63. PMID: 11809531.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    165. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    166. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 122:3336-3343.
    167. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology.
    168. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia.
    169. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leukemia Research. 44:1-7.
    170. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.
    171. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia.
    172. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica. 101:e324-e327.
    173. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    174. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. American Journal of Hematology. 91:E274-E276.
    175. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 7:14251-14258.
    176. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma, Myeloma and Leukemia. 16:616-624.
    177. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.
    178. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 122:238-248.
    179. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. American Journal of Hematology. 90:E211-E212.
    180. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    181. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    182. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 16:S67-S73.
    TAKAHASHI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (502)
    Explore
    _
    Co-Authors (117)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _